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Abstract
Background: Inflammatory mechanisms involving complement activation has been shown to take part in the
pathophysiology of congestive heart failure, but the initiating mechanisms are unknown. We hypothesized that the main
initiator molecules of the lectin complement pathway mannose-binding lectin (MBL), ficolin-2 and ficolin-3 were related to
disease severity and outcome in chronic heart failure.
Methods and Results: MBL, ficolin-2 and ficolin-3 plasma concentrations were determined in two consecutive cohorts
comprising 190 patients from Hungary and 183 patients from Norway as well as controls. Disease severity and clinical
parameters were determined at baseline, and all-cause mortality was registered after 5-years follow-up. In univariate analysis
a low level of ficolin-3, but not that of MBL or ficolin-2, was significantly associated with advanced heart failure (New York
Heart Association Class IV, p,0.001 for both cohorts) and showed inverse correlation with B- type natriuretic peptide (BNP)
levels (r =20.609, p,0.001 and r =20.467, p,0.001, respectively). In multivariable Cox regression analysis, adjusted for age,
gender and BNP, decreased plasma ficolin-3 was a significant predictor of mortality (HR 1.368, 95% CI 1.052–6.210; and HR
1.426, 95% CI 1.013–2.008, respectively). Low ficolin-3 levels were associated with increased complement activation product
C3a and correspondingly decreased concentrations of complement factor C3.
Conclusions: This study provides evidence for an association of low ficolin-3 levels with advanced heart failure. Concordant
results from two cohorts show that low levels of ficolin-3 are associated with advanced heart failure and outcome. The
decrease of ficolin-3 was associated with increased complement activation.
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Introduction
Chronic heart failure (CHF) is initiated by a variety of insults,
including myocardial infarction and ischemic heart disease,
hypertension, valvular abnormalities, as well as various forms of
cardiomyopathies, which result in impaired myocardial function
[1]. Following an initial impairment, there is an adaptive
compensatory response to preserve the overall function. These
compensatory responses may in turn eventually lead into
maladaptive responses with development of progressive myocar-
dial dysfunction and overt heart failure. Several studies have
suggested the involvement of innate immunity and inflammation
in these maladaptive responses, but at present, the underlying
molecular mechanisms are only partly clarified [2].
The complement system represents an important branch of
inflammation and innate immunity [3]. Complement activation
occurs in CHF [4] and has been associated with adverse clinical
events in patients with symptomatic heart failure [5,6]. Deposition
of the terminal complement complex (TCC) has been observed in
myocardial biopsies from patients with dilated cardiomyopathy
[7], but its relation to disease severity in cardiomyopathy is
debated [8].
Activation of the complement system is mediated via three
different routes: the classical-, the lectin- and the alternative
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e60976
pathways, which all lead to activation of the central complement
component C3 and subsequently C5 with generation of C5a and
TCC. In humans five recognition molecules of the lectin pathway
have been described: mannose-binding lectin (MBL), ficolin-1 (M-
ficolin), ficolin-2 (L-ficolin) and ficolin-3 (H-ficolin or Hakata
antigen) and lately also collectin-11 [9,10]. Ficolin-3 is the
predominant plasma molecule with a median concentration in
healthy Caucasians of 25 mg/ml, followed by ficolin-2 (5 mg/ml)
and MBL (1 mg/ml), respectively [11–13]. By contrast, ficolin-1
and collectin-11 normally circulates at very low plasma levels
[14,15]. There appears to be a hierarchy in the complement
activation potential between the lectin pathway initiators, as
ficolin-3 has the strongest potential, MBL and ficolin-2 are
intermediate, while ficolin-1 and collectin-11 may have the
smallest potential [10,16].
Because these molecules bind altered self and dying host cells we
hypothesised that one of the underlying mechanisms of the
observed complement activation seen in patients with heart failure
could be due to involvement of lectin initiator molecules, reflected
as possible consumption. Thus, we investigated the possible
association between the main lectin pathway initiators MBL,
ficolin-2 and ficolin-3 and clinical, hemodynamic and neurohor-
monal parameters of disease severity, as well as outcome in two
independent prospectively designed cohorts of CHF patients
originating from Hungary and Norway.
Results
Study Cohorts
One-hundred and ninety (Hungarian cohort, New York Heart
Association (NYHA) functional class I-IV) and 183 (Norwegian
cohort, NYHA II-IV) patients with stable CHF were consecutively
included in the study (Table 1). The etiology of CHF was
determined on the basis of disease history, coronary angiography
and echocardiography. The main difference between the two
cohorts was in the survival rates: 44% of the Hungarian and 69%
of the Norwegian cohorts survived the 5 year long follow-up
period. In addition, patients in the Hungarian cohort were older,
with male predominance and had increased prevalence of
ischemic heart disease as compared to the Norwegian cohort.
Accordingly, concomitant atherosclerotic and related diseases such
as hypertension, type-2 diabetes mellitus and previous myocardial
infarction were more prevalent in the Hungarian cohort than in
the Norwegian cohort.
Lectin Complement Pathway Components in CHF
No significant differences for MBL or ficolin-2 concentrations
between patients and controls, or across NYHA classes, were
observed in either of the cohorts (Figure 1 A–D). However, the
patients in both cohorts had markedly lower levels of ficolin-3 as
compared to healthy controls (both p,0.001), with gradually
decreasing levels according to disease severity (Figure 1 E–F). The
difference in ficolin-3 levels remained significant after adjustment
for age- and gender (data not shown). The lowest ficolin-3 levels
were observed in patients with NYHA class IV. According to the
results of Dunnet’s post test, ficolin- 3 levels were significantly
lower in patients with NYHA class IV (p,0.01) and class III
(p,0.01), as compared to class I patients (Hungarian cohort),
whereas in the Norwegian cohort a significant difference was
observed between class II and class IV patients (p,0.05). The
median concentrations of ficolin-3 across CHF severity classes
NYHA II-IV were very similar in the two cohorts: 16.9–15.6–
13.3 mg/ml for the Hungarian cohort and 20.3–16.6–13.1 mg/ml
for the Norwegian cohort.
Determinants of Low Ficolin-3 levels
To find the best cut-off level between low and high ficolin-3
levels, a receiver operating characteristic (ROC) analysis of the
ficolin-3 concentration in relation to 5 year survival was performed
in the Hungarian cohort. The optimal ficolin-3 cut-off level was
found to be 15.0 mg/ml. This level was used for further analyses to
discriminate between low and high ficolin-3 levels throughout in
both cohorts. Using this cut-off level it was revealed that a low
ficolin-3 level was associated with decreased body mass index
(BMI, p,0.001), low total cholesterol (p,0.001) and increased N-
terminal pro-brain natriuretic peptide (NT-proBNP, p,0.001)
concentrations in both cohorts. Importantly, no associations with
hepatic parenchymal enzymes (i.e., ASAT or ALAT) were
observed in either cohort (Table 2). Moreover, no relationship
between age or gender, and ficolin-3 levels was observed.
Interestingly, we found a significant inverse correlation between
ficolin-3 levels and NT-proBNP as a marker of increased
myocardial cell wall stress in both cohorts (Figure 2 A–B)
(rho=20.566, p,0.001 and rho=20.459 p,0.001 for the
Hungarian and Norwegian cohorts, respectively). Patients with
low ficolin-3 levels were further characterized by low C3 levels in
both cohorts (Table 2 and Figure 2 C–D). Again, the shape and
strength of associations were very similar in the two cohorts
(rho= 0.417, p,0.001 and rho= 0.411, p,0.001 for the Hun-
garian and Norwegian cohorts, respectively). The plasma levels of
the C3 activation marker C3a (measured only in the Hungarian
cohort) inversely correlated with ficolin-3 (rho=20.198,
p = 0.008) and high C3a levels were associated with low ficolin 3
concentrations (Table 2). These associations between ficolin-3 and
NT-proBNP as well as C3 remained significant after multivariable
adjustment (Table S1) for both cohorts.
Prediction of 5-year Mortality in CHF by Baseline ficolin-3
levels
During a median follow up of 51 and 67 months (interquartile
ranges: 21–60, 32–75, respectively), 107 and 49 patients died in
the Hungarian and Norwegian cohorts, respectively (5-year
mortality rate 0.56 and 0.27). Ficolin-3 levels were stratified
according to the above mentioned ROC analysis and 15.0 mg/ml
was determined as cut-point with optimum sensitivity (0.505) and
specificity (0.759) to predict all-cause mortality in the Hungarian
cohort. Univariate Kaplan-Meier survival curves for patient
groups with low or high ficolin-3 levels in the two cohorts,
showing an association between low (,15.0 mg/ml) baseline
ficolin-3 level and increased all-cause mortality in the Hungarian
(p,0.001) and a similar tendency in the Norwegian cohort cohorts
(p = 0.072) (Figure 3). Ficolin-3 levels showed significant prediction
of mortality in both cohorts in the univariate Cox regression
analysis (HR 1.709 and 1.471 per 1-SD decrease of ficolin-3). In
multivariable age- and gender adjusted models (Table 3, model 1)
low baseline ficolin-3 was associated with a significantly increased
risk of mortality in both cohorts. Further adjustment for NT-
proBNP (Table 3, model 2) had only minor influence on this
association with a significant association of ficolin-3 with total
mortality in both cohorts (Table 3). Finally, as shown in Table S2,
ficolin-3 remained a significant predictor of mortality in both
cohorts if BMI, diabetes mellitus, haemoglobin, or creatinine (one-
at-a-time) was added to model 2 of Table 3 (exceptions were
haemoglobin and creatinine in the Norwegian cohort, where
borderline significance was observed). There were 18 heart
transplantations during follow-up in the Norwegian cohort. When
low baseline ficolin-3 levels were analyzed in relation to the
combined end-point transplantation and mortality, the univariate
Kaplan Meier log rank analysis was significant (p = 0.003) (data
Ficolin-3 and Chronic Heart Failure
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not shown) and the age-, gender- and NT-proBNP adjusted
analysis gave a HR of 1.575 (95% 1.106–2.242) with a Wald’s chi-
square of 6.93 (p = 0.008).
Discussion
Complement activation has been shown to be an important
inflammatory component in many diseases. The molecular
mechanisms behind the progressive loss of viable heart tissue in
CHF are only partly resolved. In this study we provide evidence,
for the first time, that ficolin-3 the main activator of the lectin
complement pathway may be associated with advanced heart
failure. Firstly, decreasing ficolin-3 concentrations were associated
with disease severity in CHF patients as assessed by clinical NYHA
classification and strongly inversely correlated with neurohormon-
al NT-proBNP assessment as a marker of myocardial cell wall
stress. Secondly, low ficolin-3 levels were related to high
concentrations of C3a levels, combined with decreased C3
concentration, linking ficolin-3 levels with complement activation.
Finally, low baseline ficolin-3 levels were associated with 5-year
mortality. Importantly these data were consistently obtained in
two independent cohorts from two different countries.
The lectin pathway initiator molecules MBL, ficolin-2 and
ficolin-3 have all been shown to serve as bridging molecules
between apoptotic bodies and phagocytic cells [17–20]. For the
ligand specificity of ficolin-3 it is known that altered self structures,
mainly yet unidentified non-carbohydrate acetylated molecules,
are recognized [21]. This interaction is currently best modeled
in vitro by the application of acetylated albumin as target
molecule. Using this in vitro model system ficolin-3 clearly induces
complement activation with deposition of C4, C3 and TCC [22].
Myocytes die by multiple mechanisms in failing hearts, including
necrosis, apoptosis, oncosis and autophagy, and these processes are
linked with complement activation [23,24]. A link between
complement activation and myocardial failure was further
supported by Oliveira et al. showing that increased deposition of
TCC in failing myocardium was normalized after prolonged
mechanical circulatory support [25]. Compiling these previous
observations together with the present ficolin-3 data we suggest
that myocardial cell death and altered self structures in the failing
human heart may bind ficolin-3, leading to reduced plasma levels
and induction of complement activation. The following observa-
tions support this conclusion. First, decreased ficolin-3 levels were
linked with more severe heart failure, as indicated by significant
associations with high NT-proBNP levels and advanced NYHA
functional class groups. In addition, ficolin-3 levels showed
correlation with complement C3 activation as judged by increased
C3a and reduced C3 reflecting consumption. No such correlation
was seen for MBL and ficolin-2 (data not shown). A scenario could
be that the low ficolin-3 levels are due to consumption because of
binding to altered self structures in the myocardial cell wall, which
is followed by complement activation, leading to inflammation and
tissue damage. In this regard it should be noted that ficolin-3 is by
far the most potent activator of the lectin pathway of complement,
independent of differences in the circulating levels of the proteins
[26].
The majority of complement proteins, including MBL, ficolin-2
and ficolin-3 are produced in the liver and an alternative
explanation for the decreased ficolin-3 levels in CHF could be
related to a decreased hepatic production and output. Indeed, the
synthetic capacity of the liver may be decreased due to hepatic
congestion caused by a decreased right ventricular function. We,
therefore, investigated whether hepatic congestion could contrib-
ute to lower ficolin-3 levels in our patient cohorts. We found,
however, that activities of hepatic parenchymal enzymes ASAT
and ALAT, markers of liver dysfunction, were not associated with
lower ficolin-3 levels making a scenario of decreased synthesis less
probable. Furthermore, low levels of MBL and ficolin-2, which
Table 1. Baseline clinical characteristics in the two cohorts.
Variable Hungarian cohort, n = 190 Norwegian cohort, n = 183
Age 69 (59–77) 58 (50–64)
Male (%) 141 (74) 143 (74)
Cause of CHF: CAD/IDCM/other (%) 108/41/41 (57/21.5/21.5) 76/96/8 (42/53/5)
NYHA Class I/II/III/IV (%) 38/62/67/23 (20/33/35/12) 0/51/79/49 (0/28.5/44/27.5)
Hypertension (%) 131 (69) 27 (15)
T2DM (%) 72 (38) 22 (12)
Previous infarction (%) 77 (41) 62 (34)
LVEF (%) 34 (27–40) 29 (20–40)
ACE-I or ARB (%) 130 (68) 155 (85)
Beta blocker (%) 128 (67) 146 (80)
Loop diuretics (%) 141 (74) 130 (71)
Statins (%) 75 (39) 79 (43)
Warfarin (%) 76 (40) 81 (45)
ASA (%) 72 (38) 78 (43)
Creatinine (mM/L) 96 (78–136) 89 (78–110)
CRP 6.2 (2.9–13.7) 3.6 (1.8–7.9)
NT-proBNP (pM/L) 680 (373–1561) 235 (92–497)
CAD: coronary artery disease; IDCM: idiopathic dilative cardiomyopathy; NYHA: New York Heart Association; T2DM: Type-2 diabetes mellitus; LVEF: Left-ventricular
ejection fraction; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; ACE-I: angiotensin converting enzyme inhibitor; ASA: Acetyl-salicylic acid;
there were missing data in 3 and 4 cases (Norwegian cohort for etiology and NYHA class).
doi:10.1371/journal.pone.0060976.t001
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Figure 1. Association of MBL (panels A–B), ficolin-2 (C–D) and ficolin-3 (E–F) levels with severity of CHF. P values of non-parametric
Kruskall-Wallis test are indicated across NYHA class groups, stars indicate results of Dunnet’s post hoc test (*p,0.05, **p,0.01; as compared to NYHA
I on panel E and NYHA II on panel F). Medians, 25 and 75 percentiles and ranges are indicated on logarithmic scales.
doi:10.1371/journal.pone.0060976.g001
Ficolin-3 and Chronic Heart Failure
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both are synthesized in the liver, were not related to CHF severity
in our cohorts. These results collectively indicate that the
decreased ficolin-3 levels observed in advanced CHF patients
were not a result of decreased synthesis by the liver.
It may also be suggested that individuals with low levels of
ficolin-3 were predisposed to CHF because of an inherited trait in
the FCN3 gene. Screening of the FCN3 gene and the promoter
have not revealed genomic alterations that may explain inter-
individual variation in ficolin-3 plasma concentration as a cause of
the observations made in the present study [11] even though a rare
deletion in the FCN3 gene may give rise to a novel immunode-
ficiency syndrome [27].
An increasing number of recent clinical studies have addressed
the potential role of ficolin-3 in different inflammatory and in
ischemia-reperfusion related conditions. It has been shown that
the lectin complement pathway activated by ficolin-3 may be
involved in C4d deposition on peritubular capillaries in kidney
allografts, and that this process is related to the pathogenesis of
humoral rejection [28]. It has also been shown that high pre-
transplant levels of ficolin-3 are associated with kidney graft
survival [29]. Ficolin-3 appears to be consumed in preeclampsia
and binds to apoptotic placentas [30]. Moreover, ficolin-3 has
been shown to be decreased in patients with diabetic nephropathy
[31], and that it varied significantly between type 2 diabetes
patients and controls [32]. Recently, our group reported that
concentrations of ficolin-3 were significantly decreased in both the
admission and in the follow-up samples of patients with definite
ischemic stroke as compared to healthy subjects [33]. An inverse
correlation was observed between low ficolin-3 levels and high
concentration of S100beta, an indicator of the size of cerebral
infarct suggesting that ficolin-3 contributes to the pathogenesis of
ischemic stroke. In line with these data our results suggest that
ficolin-3 also could be related to the progression of CHF.
It should be noted that the survival rate in the Norwegian
cohort is better even though the ratio of patients with a more
severe NYHA classification is higher than in the Hungarian
cohort. This seemingly paradoxical finding is probably due to the
pronounced heterogeneity between the two cohorts (higher age,
male predominance and higher proportion of ischemic heart
disease in the Hungarian cohort, differences in the origin and
genetic background of the two population), but could also reflect
underlying differences in the health system between the two
countries.
There are particular strengths of this study. We made the
observations of low ficolin-3 levels in advanced CHF in two
independent cohorts making the problem of type one error
mistake less likely. Although there were significant baseline clinical
differences between the two cohorts (Table 1), low ficolin-3 were
Figure 2. Univariate correlation of ficolin-3 levels with NT-proBNP (A and B) and complement C3 (C and D). Pearson’s correlation
coefficients and p values are indicated.
doi:10.1371/journal.pone.0060976.g002
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Table 2. Baseline clinical characteristics according to ficolin-3 levels (median, IQ range, or n (%)).
Variable Hungarian cohort Norwegian cohort
Ficolin-3 levels, mg/ml, ,15.0 ug/ml, n = 75 .= 15.0 mg/ml, n = 115 ,15.0 mg/L, n = 75 .= 15.0 n = 108
Age 72 (62–78) 67 (58–76) 59 (47–64) 58 (51–64)
Male (%) 51 (68) 89 (77) 58 (78) 85 (79)
Cause of CHF: CAD/IDCM/other 44/19/12 (59/25/16) 64/22/29 (56/19/25) 33/37/4 (45/50/5) 43/59/4 (41/56/4)
NYHA Class I/II/III/IV 7/23/31/14 (9/31/41/19)** 32/38/37/8 (28/33/32/7) 0/13/33/27 (0/18/45/37)* 0/38/46/22 (0/36/43/21)
Hypertension (%) 45 (60)* 85 (74) 9 (12) 18 (16)
T2DM (%) 24 (32) 48 (42) 7 (9) 15 (14)
Previous infarction (%) 31 (41) 45 (39) 25 (34) 37 (34)
LVEF (%) 31 (23–35)*** 38 (30–41) 27 (20–36) 30 (22–40)
ACE-I or ARB (%) 50 (67) 79 (69) 65 (87) 90 (83)
Beta blocker (%) 50 (67) 77 (67) 63 (85) 83 (77)
Loop diuretics (%) 58 (77) 83 (72) 58 (78) 72 (67)
Statins (%) 27 (36) 48 (42) 36 (49) 43 (40)
Warfarin (%) 35 (47) 40 (35) 41 (55)* 40 (37)
ASA (%) 24 (32) 48 (42) 26 (35) 52 (48)
BMI (kg/m2) 25.4 (23.7–27.9)*** 28.8 (25.0–32.1 24.4 (22.4–27.6)*** 27.0 (24.7–31.2)
Creatinine (mM/L) 99 (84–145) 94 (78–118) 99 (83–121)** 84 (71–106)
CRP 6.4 (2.8–15.9) 6.2 (3.1–12.4) 4.3 (2.2–12.0)* 3.2 (1.4–5.6)
NT-proBNP (pM/L) 2351 (794–3081)*** 730 (298–883) 376 (218–756)*** 142 (48–339)
Total cholesterol mmol/L 3.7 (3.0–4.3) *** 4.4 (3.9–5.2) 3.8 (3.0–4.6)*** 4.4 (3.5–5.2)
ASAT (U/L) 27 (19–34) 22 (19–31) 26 (22–32) 27 (22–34)
ALAT (U/L) 23 (16–38) 23 (17–36) 24 (18–36) 25 (20–39)
Hemoglobin (g/L) 141 (124–154) 142 (131–152) 134 (121–149)* 144 (133–150)
Complement C3 (g/L) 1.08 (0.93–1.25)*** 1.29 (1.15–1.46) 1.11 (0.95–1.26)*** 1.27 (1.12–1.50)
Anaphylatoxin C3a 268.5 (198.7–382.1) 208.8 (120.5–339.3) n.d. n.d.
*p,0.050.
**p,0.010.
***p,0.001;
n.d.: not done.
CAD: coronary artery disease; IDCM: idiopathic dilative cardiomyopathy; NYHA: New York Heart Association; T2DM: Type-2 diabetes mellitus; LVEF: Left-ventricular
ejection fraction; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; ACE-I: angiotensin converting enzyme inhibitor; ASA: Acetyl-salicylic acid;
ASAT: aspartate aminotransferase; ALAT: alanin aminotransferase.
doi:10.1371/journal.pone.0060976.t002
Figure 3. Kaplan-Meier plot of baseline ficolin-3 levels (,15.0 mg/ml, thick line and .= 15.0 mg/ml, thin line) and long term survival
(all-cause mortality) in patients with CHF. Log-rank test for the Hungarian cohort (panel A) and for the Norwegian cohort (panel B) is indicated.
doi:10.1371/journal.pone.0060976.g003
Ficolin-3 and Chronic Heart Failure
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strikingly similar in analytical terms in the different NYHA
functional class groups. However, disease severity was assessed by
only NYHA functional class and biomarkers, and 6-min walking
test was not studied. These observations indicate that disease
activity related factors, rather than concomitant clinical confound-
ers, regulate ficolin-3 levels in the two cohorts. Potential limitations
of the study are the study design that precluded serial samples from
each patient in different stages of the disease course, the number of
patients included and the lack of specific causes of death allowing
analyzing all-cause mortality only.
In conclusion, our results show that ficolin-3 levels are
associated with disease severity in CHF and long term outcome.
The inverse correlation with C3a and the correlation with C3
levels link this observation directly to complement activation
suggesting that ficolin-3 may be important in aggravation and
progression of CHF.
Materials and Methods
Hungarian Cohort
One-hundred and ninety consecutive patients with clinical signs
of CHF according to the New York Heart Association (NYHA)
functional class I-IV and with left ventricular ejection fraction
(LVEF) ,45% independent of etiology were included in this
observational study from the out- or inpatient cardiology
departments (Table 1). All of the patients included from the
inpatient department were in as compensated fluid state, as it was
possible for the given patient, when blood was taken for biomarker
determinations (before leaving the hospital). Patients with co-
existing malignant or acute infectious conditions were not
included. The patients were contacted at year 5 after inclusion
and clinical status was registered. Information on mortality (with
specific cause of death) was collected from the hospital database,
medical records or from family members. Healthy Hungarian
controls (n = 100, 54 women; mean6SD age 3668.9 years) were
recruited in an outpatient department in Budapest providing
regular health checkup for healthy employees on a mandatory
basis.
Norwegian Cohort
One-hundred and eighty three patients with stable CHF
according to NYHA functional class group II-IV independent of
etiology were consecutively included in this observational study
(Table 1). In the Norwegian sub-study, the actual department of
cardiology is a tertiary referral centre for evaluation of patients for
heart transplantation or other forms of invasive intervention. All
patients were in a stable phase, with no change in medication
during the preceding three months. Patients with acute coronary
syndromes during the last 6 months and patients with significant
concomitant disease, such as infection, malignancy, or autoim-
mune disease, were excluded. The patients were contacted 4.62
years (mean) after inclusion and all-cause mortality was registered
based on the data from the Norwegian National Board of Health
Registry. Control subjects were 20 sex- and age-matched healthy
individuals from the same area of Norway as the patients (17 men
and 3 women; mean6SD age 5667 years).
Ethics
Both studies were carried out in accordance with the Helsinki
Declaration. The study protocols were approved by the individual
Local Ethics Committees: The Institutional Ethics Committee of
Semmelweis University in Budapest and The Research Ethics
Committee South East under the University of Oslo. Written
informed consent approved by the Local Ethical Committees was
obtained from all individuals.
Laboratory Methods
The plasma concentrations of the MBL [34], ficolin-2 [12] and
ficolin-3 [11] were determined by established ELISA-based
methods. Briefly, microtiter plates were coated with either
monoclonal anti-MBL antibody (HYB-131-01) or monoclonal
anti-ficolin-2 antibody (FCN216) or monoclonal anti-ficolin-3
antibody (FCN334) in phosphate buffered saline (PBS) overnight
at 4uC. Samples diluted 1:25 and 1:400 for MBL, 1:50 for ficolin-2
or 1:640 for ficolin-3 in sample buffer (PBS-T with 1% mouse
serum and bovine serum) were added in triplets to washed wells
and incubated for 3 hours at 37uC. MBL was detected with
biotinylated monoclonal anti-MBL antibody (HYP-131-01), fico-
lin-2 was detected with biotinylated monoclonal anti-ficolin-2
antibody (FCN219) and ficolin-3 was detected with biotinylated
monoclonal anti-ficolin-3 antibody (FCN334) by incubation
overnight at 4uC. Washed wells were incubated for 1 hour at
37uC with HRP-conjugated streptavidin. Plates were developed
for 15 minutes with OPD (o-phenylenediamine) substrate solution
and stopped by adding 1M H2SO4. The optical density was
measured at 490 nm. As standard was used a serum pool which
has been calibrated towards recombinant MBL, ficolin-2 and
ficolin-3 and thus contain known concentrations of the different
proteins. Lower limit of detection in these assays is 20 ng/ml of
MBL, 5 ng/ml of ficolin-2 and 1 ng/ml of ficolin-3, respectively.
The inter-assay coefficient of variation (CV) is 8.0%, 7.1% and
Table 3. Results of multivariable Cox proportional-hazards regression analyzing effects of ficolin-3 for all-cause mortality.
HR* 95% CI x2** p
Hungarian cohort
Ficolin-3, univariate 1.709 1.317–2.212 ,0.001
Ficolin-3, model 1 (adjusted for age and sex) 1.669 1.283–2.169 17.55 ,0.001
Ficolin-3, model 2 (adjusted for age, sex and NT-proBNP) 1.368 1.052–1.776 6.210 0.013
Norwegian cohort
Ficolin-3, univariate 1.471 1.106–1.957 0.008
Ficolin-3, model 1 (adjusted for age and sex) 1.457 1.039–2.041 5.194 0.023
Ficolin-3, model 2 (adjusted for age, sex and NT-proBNP) 1.426 1.013–2.008 4.436 0.035
*Hazard ratio for ficolin-3 shown as standardized hazard ratio (HR per 1 SD decrease); age was considered as time-dependent covariate.
**Wald x2 of likelihood-ratio test.
doi:10.1371/journal.pone.0060976.t003
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4.7% and the intra-assay CV 5%, 4.3% and 3.9% for the MBL,
ficolin-2 and ficolin-3 assays, respectively.
For the Hungarian cohort, C3 levels were measured by Roche
Cobras Integra 800 (Tina-quantH C3c 2. Cat. No.: 3001938).
Levels of C3a (C3a des-arg, Quidel, San Diego, CA, USA), and N-
terminal pro-brain natriuretic peptide (NT-proBNP) (Biomedica
ELISA kit (Cat No. BI-20852) were determined by commercial
ELISA kits according to the manufacturer’s instructions. Other
laboratory parameters including C-reactive protein (CRP) were
measured by Roche Integra 800, or by Cell-Dyn 3500 hematology
analyzer.
For the Norwegian cohort NT-proBNP and CRP levels were
assayed on a MODULAR platform (Roche Diagnostics, Basel,
Switzerland). C3 levels were determined using nephelometry (BN
Prospec, Siemens Healthcare Diagnostics, Deefield, IL) according
to the manufacturer’s instructions. Other parameters were
measured on a Roche/Hitachi 917 analyzer (Roche Diagnostics,
Mannheim, Germany).
Samples were taken at inclusion time. For both cohorts samples
were drawn in dry, citrate or EDTA containing vacutainer tubes.
All samples were stored at 280uC.
Statistical Analysis
For descriptive purposes the values of each measurement are
given as median and 25th–75th percentile, or as numbers (percent),
since most of the variables were not normally distributed. Non-
parametric tests were used for group comparisons in case of
clinical variables (Table 1); continuous variables between two
groups were compared with Mann-Whitney U test and with more
groups with Kruskall-Wallis test, whereas categorical variables
were compared with Pearson’s x2 test. Ficolin-3 showed skewed
distribution, therefore, group comparisons were done by para-
metric ANOVA on log-transformed values. Accordingly, correla-
tion analysis of ficolin-3 and other markers was done by the
Pearson’s method on log-transformed variables. Multiple linear
regression models with stepwise forward selection process (with an
F value .1 to select into the model on log-transformed or
categorical variables) was also applied. Kaplan-Meier analysis and
log-rank test was used to analyze survival across different strata.
Ficolin-3 was fitted to univariate and multivariate Cox propor-
tional hazard model to assess the effect on CHF event free survival.
Survival times were measured from inclusion in the study until
mortality of any cause. The results of the Cox regression models
are presented as hazard ratios (HR) standardized on 1-SD
decrease of ficolin-3, the corresponding 95% confidence intervals
(CI) and the Wald chi-square and p values of likelihood ratio tests.
Age was analyzed as time-dependent covariate in the multivariate
models. Receiver operator characteristics (ROC) analysis was
applied in the Hungarian cohort to determine the best cut-point of
continuous variables to predict clinical events, which also were
applied to the Norwegian cohort. Statistical analyses were carried
out using the software STATISTICA 7.0 (StatSoft Inc., Tulsa,
OK, USA), SPSS 13.01 (Apache Software Foundation, USA) and
GraphPad Prism 4.03 (GraphPad Softwares Inc, CA, USA)
softwares. Two tailed p values were calculated.
Supporting Information
Table S1 Multiple linear regression showing associa-
tions between ficolin-3 and baseline clinical and labora-
tory parameters in patients with chronic heart failure.
(DOC)
Table S2 Results of multivariable Cox proportional-
hazards regression analyzing effects of ficolin-3 for all-
cause mortality.
(DOC)
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